Atrial natriuretic peptide (ANP) represents an attractive therapeutic target in hypertension and heart failure. The biologically active form of ANP is produced by the cardiac serine protease corin, and modulation of its activity might therefore represent a novel approach for ANP augmentation. MicroRNAs (miRNAs) are pervasive regulators of gene expression, but their potential role in regulating corin activity has not been elucidated. Our aim was to systematically identify and characterize miRNA regulators of corin activity in human cardiomyocytes. An assay for measuring serine protease activity in human induced pluripotent stem cell (iPS)-derived cardiomyocytes was used to perform a comprehensive screening of miRNA family inhibitors \((n = 42)\). miRNA 1-3p (miR-1-3p) was identified as a potent inhibitor of corin activity. The interaction between miR-1-3p and a specific target site in the \(3'\) untranslated region (\(3'\) UTR) was confirmed through argonaute 2 (AGO2)-RNA immunoprecipitation and reporter assays. Inhibition of miR-1-3p resulted in upregulation of \(CORIN\) gene and protein expression, as well as a concomitant increase in extracellular ANP. Additionally, miR-1-3p was found to interact with and inhibit the expression of several transcriptional activators of ANP gene expression. In conclusion, we have identified a novel regulator of corin activity and ANP biogenesis in human cardiomyocytes that might be of potential future therapeutic utility.

**KEYWORDS** atrial natriuretic peptide, cardiomyocyte, corin, heart failure, microRNA
unprocessed pro-ANP and there are numerous indications that corin activity is decreased in experimental models of HF (11–13). Therefore, corin is an interesting therapeutic target to achieve NP augmentation in HF and hypertension. However, regulation of corin expression and catalytic activity has not been extensively studied. With regard to the regulation of CORIN gene expression, Pan et al. showed that there are functional, conserved GATA4 motifs in the CORIN promoter (14) and Lee et al. proposed a mechanism whereby regulated inositol-requiring protein 1 (RIE1) promotes corin mRNA degradation in the context of HF (15).

MicroRNAs (miRNAs) are a class of short, noncoding RNAs with pervasive roles in tissue homeostasis and disease (16–19). Through base pairing with complementary sequences in the 3’ untranslated region (3’ UTR) of mRNAs, miRNAs mediate repression of specific genes through mRNA degradation or translational repression (20). The tissue-specific expression of many miRNAs, combined with the relative ease with which miRNAs can be modulated in vivo, has made these molecules attractive therapeutic targets across a wide range of disease states, including cardiovascular disease (21).

miRNAs have been implicated in the regulation of ANP biogenesis, but only through direct binding to NPPA mRNA (22, 23). In the present study, we have conducted an unbiased, large-scale functional screening of miRNAs that inhibit corin activity in human cardiomyocytes. Such miRNAs could ultimately constitute therapeutic targets for NP augmentation.

RESULTS

Adaptation and validation of an assay for measuring corin activity in human cardiomyocytes. We applied the principle of the cardiac serine protease activity assay described by Chen et al. (13) to human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM). First, the expression of CORIN in iPS-CM was assessed with reverse transcription-quantitative PCR (qRT-PCR) and found to be comparable to that in human atrial tissue (Fig. 1a). The presence of corin protein on the cell membrane of iPS-CM cells was confirmed using flow cytometry (Fig. 1b). Corin activity was measured by adding a fluorogenic bisamide substrate of rhodamine 110 containing two serine protease cleavage sites, (p-tosyl-Gly-Pro-Arg)$_2$-Rh$110$, to cells in culture and monitoring the increase in fluorescence over time (Fig. 1c). The reaction progress curves were linear across a range of substrate concentrations (0.1 to 20 μM) (Fig. 1d), indicating that initial reaction velocity ($V_0$) conditions were met. To test the validity of the assay, enzyme kinetics were compared between untreated control cells, cells treated with 2 mM serine protease inhibitor benzamidine, and cells transfected with CORIN small interfering RNA (siRNA). Successful knockdown of CORIN gene expression was confirmed with qRT-PCR (Fig. 1e). As expected, there was a 50% reduction in maximal reaction rate ($V_{max}$) with the addition of benzamidine (from $V_{max}$ of 4.01 [95% confidence interval (CI), 3.3 to 4.98] in control cells to $V_{max}$ of 1.81 [95% CI, 1.57 to 2.1] in benzamidine-treated cells). Knockdown of CORIN mRNA reduced $V_{max}$ by 25% (to $V_{max}$ of 2.0 [95% CI, 2.5 to 3.3]). Neither of the treatments significantly affected $K_m$ (Fig. 1f). Taken together, these results indicate that the assay is sensitive to cardiac serine protease activity in general and corin activity specifically.

Screening of an miRNA family inhibitor library. To identify miRNAs that affect corin activity in human cardiomyocytes, an miRNA inhibitor library was screened. To simplify the screening procedure, we utilized a library with inhibitors directed at miRNA families, rather than individual miRNAs. Members of an miRNA family share a “seed” sequence, i.e., the nucleotides at positions 2 to 8 of the miRNA which bind to target mRNAs. The library contained locked nucleic acid (LNA) antisense inhibitors for 42 miRNA families, covering a total of 144 individual miRNAs (see Table S1 in the supplemental material for detailed information about the miRNAs included). Human iPS-CM were transfected with the miRNA family inhibitor library 72 h prior to assaying serine protease activity. The initial reaction velocity ($V_0$) at 20 μM substrate was used as the endpoint for screening (Fig. 2a). Six miRNA family inhibitors (corresponding to the miRNA 1 [miR-1], -10, -103, -132, -146, and -519 families) caused statistically
significant increases in enzyme activity ($P < 0.05$), but only the result for the miR-1 inhibitor remained significant after adjusting for multiple comparisons (false discovery rate $q < 0.05$) (Fig. 2b). There were no examples of miRNA families where inhibition led to a decrease in corin activity. Inhibition of the miR-1 family caused a 10-fold increase in enzyme activity compared to the activity in the negative control. The miR-1 family consists of two members, miR-1-3p and miR-206 (Fig. 2c), whose expression is restricted almost exclusively to cardiac and skeletal muscle, respectively (24, 25). In fact, miR-1-3p was ranked as the single most tissue-specific miRNA in a recent study (25). Moreover, miR-1-3p is one of the most abundant miRNAs in cardiomyocytes, with reported roles in cardiac development (26) and disease (27–29). We confirmed that miR-1-3p was the predominant miR-1 family member in iPS-CM, as well as in human atrial and ventricular tissue (Fig. 2d). Given the cardiac expression profile of miR-1-3p, we chose to focus the remainder of the study on this miR-1 family member. Specific inhibition of miR-1-3p in iPS-CM using an LNA antisense oligonucleotide (anti-miR-1) caused a 60% reduction in miR-1-3p expression (Fig. 2e) and a corresponding 50% increase in $V_{\text{max}}$ in the serine protease assay compared to the results for cells treated with a scrambled control anti-miR oligonucleotide (Fig. 2e). Moreover, miR-1 inhibition

![FIG 1](image-url)
FIG 2 Identification of miR-1 as a regulator of cardiac serine protease activity and ANP biogenesis. (a) Overview of the screening procedure. (b) Initial reaction velocity ($V_0$) for each miRNA family inhibitor ranked according to effect. Data for miRNA inhibitors that caused a statistically significant difference in $V_0$ ($P < 0.05$ using Student’s $t$ test) are shown in blue, and data for the only inhibitor whose results remained significant after adjusting for multiple comparisons ($q < 0.05$, using the false discovery rate approach), miR-1, are shown in green. Data for cells transfected with a negative-control (NC) miRNA family inhibitor are shown in red. Results are based on two separate screenings with two technical replicates each. (c) RNA sequences for the two miRNA-1 family members, miR-1-3p and miR-206, with the seed sequence shown in red. (d) Expression of miR-1-3p and miR-206 relative to that of U6 RNA in iPSC-CM and human cardiac tissue specimens of atrial and ventricular origin, measured by qRT-PCR ($n = 3$ to 6). (e) Expression of miR-1 in iPSC-CM transfected with LNA antisense inhibitor anti-miR-1 analyzed by qRT-PCR. Data are expressed relative to the mean value of the control cells (anti-miR-Ctrl). * $P < 0.05$, using Student’s $t$ test. Data are derived from three separate experiments. (f) Michaelis-Menten saturation curves for iPSC-CM transfected with anti-miR-1 or scrambled control anti-miRNA. Results are based on three separate experiments. (g) Concentrations of ANP in the supernatants of iPSC-CM transfected with anti-miR-1 or scrambled control anti-miRNA measured by enzyme-linked immunosorbent assay (ELISA). *** $P < 0.001$, using Student’s $t$ test. Data are derived from three separate experiments.
caused a significant increase in extracellular ANP from iPS-derived cardiomyocytes, adding further evidence that miR-1-3p directly affects corin activity \( (P < 0.001) \) (Fig. 2g).

**AGO2-RIP identifies corin as a direct target of miR-1.** We next sought to comprehensively map miR-1-3p mRNA targets in human cardiomyocytes that could explain the effect on corin activity. We performed RNA immunoprecipitation (RIP) with an argonaute 2 (AGO2) antibody in iPS-CM transfected with synthetic pre-miR-1 or negative-control pre-miRNA. Overexpression of miR-1-3p was validated with qRT-PCR (Fig. 3a). Coprecipitated RNA was analyzed with microarrays, and 367 mRNAs were enriched >2-fold in the AGO2 fraction following miR-1-3p overexpression (Fig. 3b, Table S2). These mRNAs included 5 validated miR-1-3p targets (CDC42 [30], FNI [31], PDIA3 [32], SARS [33], and SOD1 [34]) and 27 predicted targets (based on results from the miRNA target prediction tool Targetscan 7.2) (Table S2) \( (35) \). Interestingly, we also identified CORIN itself as one of the enriched miR-1/AGO2-associated mRNAs. Given the absence of other genes with serine protease activity or genes known to be transcriptional or translational regulators of corin in the list of miR-1/AGO2-associated RNAs, we concluded that miR-1-3p affects cardiac serine protease activity directly by interacting
with CORIN mRNA. We confirmed the enrichment of CORIN and CDC42 in the AGO2 fraction of cells overexpressing miR-1-3-p using qRT-PCR ($P < 0.01$) (Fig. 3c).

miR-1 regulates CORIN expression through direct binding to a site in the 3’ UTR. Next, we wanted to test whether miR-1-3p regulates CORIN expression through direct interaction with a target site in its 3’ UTR. We identified a poorly conserved, putative 7-mer-α target site for miR-1-3p in the 3’ UTR of CORIN mRNA using Target-scan 7.2 (Fig. 4a). Inhibition or overexpression of miR-1-3p in iPS-CM caused significant increase or decrease in CORIN gene expression (Fig. 4b), as well as the amount of

![Graphs and figures](FIG 4 miR-1 negatively regulates corin expression through binding to a site in the 3’ UTR. (a) Representation of the predicted miR-1-3p target site (red letters) in the 3’ UTR of corin mRNA. (b) Relative expression of CORIN in iPS-CM transfected with pre-miR-1 or anti-miR-1 measured by qRT-PCR. Results are derived from three separate experiments. Data are normalized to the expression of GAPDH and expressed relative to the mean value for the respective control group. **, $P < 0.01$, using Student’s t test. (c) Membrane expression of corin in iPS-CM transfected with pre- or anti-miR-1 analyzed with flow cytometry. Cells were stained with a corin antibody, and the mean fluorescence intensity (MFI) in the FL-2 channel was measured. Data are derived from three separate experiments. *, $P < 0.05$ using Student’s t test. (d) A reporter plasmid with the 3’ UTR of corin cloned downstream from the Gaussia luciferase gene (pCOR) was cotransfected with pre- or anti-miR-1 (or corresponding controls) in iPS-CM, and the luminescence signal was measured after 72 h. The signal from the passive reporter gene, encoding SEAP, was used for normalization of the luciferase signal. The results are derived from three separate experiments. **, $P < 0.01$, using Student’s t test. The reporter assay was repeated with a plasmid in which the predicted miR-1 target site had been deleted by site-directed mutagenesis (pCORΔm1) or with an empty reporter vector (pNull).
membrane-bound corin protein (Fig. 4c). To confirm the interaction of miR-1-3p with the predicted target site, a reporter construct carrying the CORIN 3’ UTR downstream from the Gaussia luciferase gene (denoted pCOR) was transfected into human iPS-CM. The reporter signal was significantly increased when inhibiting miR-1-3p via the LNA antisense inhibitor anti-miR-1 and decreased when overexpressing miR-1-3p (Fig. 4d), indicating that miR-1-3p interacts with the CORIN 3’ UTR. Deletion of the predicted target site from the reporter plasmid by site-directed mutagenesis (yielding a plasmid denoted pCORΔm1) completely abolished the ability of miR-1-3p to modulate the reporter signal, confirming the functionality of this specific sequence. Importantly, the reporter signal from the empty vector (pNull) was not affected by transfection with pre-miR-1 or anti-miR-1. These results confirm that CORIN is a direct target of miR-1-3p in human cardiomyocytes.

Additional effects of miR-1 on ANP biogenesis. Given that a single miRNA can potentially regulate numerous target mRNAs (36) and the fact that some miRNAs have a tendency to target genes with related functions (37–40), we hypothesized that the effect of miR-1-3p inhibition on extracellular ANP levels (Fig. 2g) could be explained by other targets in addition to CORIN itself. To address this hypothesis, we first made a comprehensive survey of the literature and identified a total of 20 genes with well-established roles in transcriptional or translational activation of ANP expression (Table S3). Second, we cross-referenced this list with the miR-1/AGO2-associated mRNAs and identified four overlapping genes: ATF2, MYOCD, FN1, and TBX20. ATF2, MYOCD, and TBX20 encode transcription factors that have been shown to activate the NPPA promoter (41–43), while FN1 inhibits the binding of the repressive transcription factor NRSE to the genomic locus encompassing NPPA (44). Since NPPA is predominantly expressed in atria and the phenotype of the iPS-CM used here has been described as a mixture of atrial-, ventricular, and nodal cells (45, 46), we wanted to confirm that NPPA was expressed at physiologically relevant levels. qRT-PCR was performed on iPS-CM, as well as human atrial and ventricular tissue, and NPPA was found to be considerably more highly expressed in iPS-CM than in ventricular tissue but not as highly expressed as in atria (Fig. 5a). We validated the enrichment of FN1 and TBX20 in the miR-1/AGO2 fraction (Fig. 5b). Moreover, the expression of FN1 and TBX20 was affected by modulation of miR-1-3p in iPS-CM transfected with pre- and anti-miR-1-3p (Fig. 5c). We could also identify conserved 8-mer miRNA target sites in the 3’ UTRs of FN1 using Targetscan 7.2 and a nonconserved 8-mer target site in the 3’ UTR of TBX20 by manually inspecting the mRNA sequence (Fig. 5d). In line with a model where miR-1-3p targets transcriptional activators of NPPA, miR-1-3p inhibition and overexpression resulted in significant up- and downregulation of NPPA expression, respectively (Fig. 5e). We ruled out NPPA as a direct target of miR-1-3p based on the complete absence of target sites throughout NPPA mRNA and nonenrichment of NPPA in miR-1/AGO2 RNA (Fig. 5f).

Taken together, these results indicate that in addition to targeting CORIN, miR-1-3p influences ANP biogenesis through targeting several transcriptional activators of NPPA but not NPPA itself.

DISCUSSION

The concept of enhancing natriuretic peptide (NP) bioavailability for therapeutic benefit has recently found its way to clinical implication. However, the current mode of NP augmentation via inhibition of neprilysin is unspecific and of limited benefit for certain HF subtypes. Thus, alternative therapeutic targets, preferably at the core of NP synthesis, could lead to improved efficacy and fewer adverse effects. The present study proposes a novel role for miR-1-3p in the regulation of ANP biogenesis. Through a systematic functional screening of miRNAs, the miR-1 family of miRNAs (including miR-1-3p and miR-206) was identified as potent regulators of corin activity in human cardiomyocytes. Mechanistically, miR-1-3p was shown to exert repressive effects by binding to a canonical miRNA binding site in the 3’ UTR of CORIN mRNA. Unlike previously identified transcriptional regulators of CORIN (4, 15), miR-1-3p expression is restricted almost exclusively to cardiac muscle (25). As such, therapeutic knockdown of
miR-1-3p is less likely to have extracardiac side effects, although the benefit of such treatment must be assessed thoroughly in future studies. There is evidence that transgenic overexpression of miR-1 in vivo can reverse cardiac hypertrophy and remodeling (47, 48) but also promote arrhythmia (29, 49), so any attempt at modulating miR-1 therapeutically must be performed with this balance in mind. We showed that miR-1-3p is by far the predominant miR-1 family member in human cardiomyocytes and cardiac tissue, but additional effects of the other, less prevalent member (miR-206) on corin activity cannot be ruled out.

One potential benefit of using miRNAs as drug targets is that they sometimes repress multiple genes in the same pathway (50). Interestingly, we found evidence that miR-1-3p exerts additional effects on ANP biogenesis by targeting two known transcriptional activators of the NPPA gene, FN1 and TBX20. In addition to these novel miR-1 targets, at least two previously described transcriptional activators of NPPA are also encoded by known miR-1 target genes: myocardin (MYOCD) (51) and myocardin-related transcription factor A (MRTFA) (52). Notably, MYOCD was enriched in the miR-1/AGO2 RIP fraction, thus corroborating its role as a direct miR-1-3p target in human cardiomyocytes. The fact that miR-1 seems to regulate ANP production both on the tran-

FIG 5 Additional effects of miR-1 on ANP biogenesis. (a) Enrichment of FN1 and TBX20 in AGO2-immunoprecipitated RNA from iPS-CM transfected with pre-miR-1 compared to pre-miR-Ctrl was validated with qRT-PCR. Shown are relative expression levels for the negative-control samples (IgG) and the AGO2 samples, normalized to the value for input RNA. Results are derived from three separate experiments. *, P < 0.05, and **, P < 0.01, comparing the levels of AGO2-associated RNA between cells transfected with pre-miR-Ctrl and pre-miR-1 using 2-way ANOVA with Sidak’s multiple-comparison test. (b) Relative expression of FN1 and TBX20 in iPS-CM transfected with pre- or anti-miR-1 measured by qRT-PCR. Results are derived from three separate experiments. Data are normalized to the expression of GAPDH and expressed relative to the mean value for the respective control group. **, P < 0.01, using Student’s t test. (c) Representation of the predicted miR-1-3p target sites in the 3′ UTR of AT2F2, FN1, and TBX20 mRNA. (d) Relative expression of NPPA in iPS-CM transfected with pre- or anti-miR-1 measured with qRT-PCR. Expression data were normalized to the expression of GAPDH and expressed relative to the mean value for the controls.*, P < 0.05, and ***, P < 0.001, using Student’s t test. Results are derived from three separate experiments. (e) Level of NPPA in AGO2-immunoprecipitated RNA from iPS-CM transfected with pre-miR-1 compared to the level in cells transfected with pre-miR-Ctrl measured with qRT-PCR. Shown are relative expression levels for the negative-control samples (IgG) and the AGO2 samples, normalized to the value for input RNA. Results are derived from three separate experiments. Statistical significance was determined by t test using 2-way ANOVA with Sidak’s multiple-comparison test.
scriptional and the posttranslational level adds further weight to it as a potent therapeutic target for NP augmentation.

**MATERIALS AND METHODS**

**Cells.** Human iPS-derived cardiomyocytes (iPS-CM) were bought from Cellular Dynamics International, Madison, WI. Cells were thawed and grown in plating or maintenance medium according to the manufacturer’s instructions. All treatments were carried out at day 5 postplating. Transfections were carried out using 40 nM siRNA (Thermo Fisher) or miRNA family power inhibitor (Exiqon, Vedbaek, Denmark) and Lipofectamine 3000 (Thermo Fisher, Waltham, MA) according to the manufacturer’s instructions. RNA was prepared using the mirNeasy minikit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The amount of ANP in the cell supernatant was determined with the atrial natriuretic peptide enzyme immunoassay (EIA) kit (Sigma-Aldrich) according to the manufacturer’s instructions.

**Tissue samples.** Human left atrial and ventricular cardiac biopsy specimens were obtained during routine clinical surveillance after transplantation or from explanted hearts. Patients provided written approval before participation, and the study was approved by the local ethics committee of Skåne University Hospital. The study was conducted in accordance with the principles of the Declaration of Helsinki.

Biopsy specimens were immediately submerged in RNAlater (Thermo Fisher) and stored at –80°C. For RNA preparation, the biopsy specimens were placed in QIAzol and homogenized with an Omni TH rotor-stator homogenizer (Omni International, Kennesaw, GA). Total RNA was prepared using the mirNeasy minikit (Qiagen) according to the manufacturer’s instructions.

**Assay for serine protease activity in cardiomyocytes.** The assay has been described previously (13) but was adapted to human cardiomyocytes. A fluorogenic bisamide derivative of rhodamine 110 (Rho110, 50 nM), 3 M sodium acetate, and 2-propanol were added to the aqueous phase and incubated for 6 h at room temperature. Next, Rho110 substrate was diluted in 10 mM Tris buffer and added to each well and fluorescence was monitored immediately and every 5 min for 60 min using a VictorX multilabel counter (Perkin Elmer, Waltham, MA). Linearity of the reaction progress curves was confirmed over a range of substrate concentrations (0.1 to 20 μM), indicating that initial reaction velocity (V₀) conditions were met. Vmax and Ks were obtained from Michaelis-Menten saturation curves.

**miRNA family inhibitor screening.** The miRCURY LNA miRNA family power inhibitor library (Exiqon, Vedbaek, Denmark), containing inhibitors for 40 miRNA families, was used for screening. iPS-CM were seeded as described above and transfected on day 5 after plating. Cells were transfected with 40 nM miRNA family power inhibitors using Lipofectamine 3000 according to the manufacturer’s instructions. Seventy-two hours after transfection, medium was aspirated, cells washed once with PBS, and Rho110 substrate added to each well. Fluorescence was measured as described above. Two separate experiments were performed, and the Vmax at 20 μM substrate was used as an endpoint in the screening. The effect of miRNA family inhibition on enzyme activity compared to that of a negative-control inhibitor was analyzed using multiple t tests with adjustment for multiple comparisons according to the principle of false discovery rate (q) (53). A q value of <0.05 was used as the threshold for statistical significance.

**qRT-PCR.** For analysis of miRNA expression, cDNA was synthesized using the miRCURY LNA universal reverse transcription (RT) kit and added to quantitative PCR (qPCR) mixtures containing miRCURY LNA primer sets (Exiqon) specific for miR-1-3p, miR-206, or U6 and 2 × fast SYBR green master mix (Thermo Fisher).

For analysis of miRNA expression, cDNA was synthesized using the RevertAid first-strand cDNA synthesis kit with random hexamer primers and used in qPCRs with TaqMan assays specific for CORIN, NPPA, CDC42, ATF2, FN1, TBX20, and GAPDH (Thermo Fisher) and 2 × universal TaqMan master mix (Thermo Fisher). All qPCRs were run on a StepOnePlus real-time PCR system (Thermo Fisher), and C̄ values were normalized first to those of their respective reference genes (GAPDH for miRNA and U6 RNA for miRNA expression) and second to the mean value for the control samples (ΔΔC̄) and were expressed using the 2−ΔΔC̄ formula.

**Flow cytometry.** iPS-CM were cultured and transfected with pre- and anti-miR as described above. Seventy-two hours after transfection, 100,000 cells were trypsinized, stained with a corin antibody (1:200, MAB2209; Biotechnne, Minneapolis, MN), and then washed and stained with a phycoerythrin (PE)-conjugated rat IgG antibody (1:400; R&D Systems). After washing, the mean fluorescence intensity of gated cells in the FL-2 channel was assessed using an Accuri C6 flow cytometer (BD Biosciences, Franklin Lakes, NJ). Cells stained with only secondary antibody were used as a negative control.

**AGO2-RIP.** Amounts of 1 × 10⁶ iPS-CM were seeded in 10-cm² cell culture dishes. On day 5 postplating, cells were transfected with 40 nM hsa-pre-miR-1 (catalog number AM17150; Thermo Fisher) or pre-miR-negative control (pre-miR-Ctrl) (catalog number AM17110; Thermo Fisher) for 72 h. RIP was performed using the Imprint RIP kit (Sigma-Aldrich) according to the manufacturer’s instructions. Cells were lysed in mild lysis buffer, including protease inhibitor cocktail, 1 M dithiothreitol (DTT), and RNase inhibitor (40 U/μl). Ten percent of the total RIP lysate was set aside as an input control. IPs were performed overnight with magnetic beads prebound with anti-Argonaute-2 antibody (5 μg, ab23831; Abcam, Cambridge, UK) or 5 μg IgG negative-control antibody. RNA was purified using phenol-chloroform extraction. TRIzol and chloroform were added to the RIP reaction mixture containing the beads, and the mixture was vortexed and centrifuged for 10 min at 16,000 × g at 4°C. Glycogen (5 mg/ml), 3 M sodium acetate, and 2-propanol were added to the aqueous phase and incubated for 6 h
at −80°C to precipitate the RNA. After centrifugation and washing with 80% ethanol, the RNA was resuspended in nuclease-free water. Input control RNA and immunoprecipitated RNA were purified with the RNA Clean & Concentrator kit (Zymo Research, Irvine, CA) and analyzed with Human Gene 1.0 ST microarray or qRT-PCR. For microarray data, experimental quality control analyses were performed using the Expression Console software version 1.4.1.46 (Thermo Fisher Scientific). Probe summarization and data normalization were performed with the robust multiarray analysis (RMA) (54) method in the Expression Console software. Expression values were normalized to those of the input control and compared between pre-miR-1 and pre-miR-Ctrl samples. Enriched miRNAs were defined as those that were increased >2-fold in the pre-miR-1 group compared to their levels in the pre-miR-Ctrl group. qRT-PCR analysis of immunoprecipitated RNA was performed essentially as described above.

**3′ UTR reporter assay.** For validation of the predicted miR-1 target site in the 3′ UTR of CORIN, an miTarget miRNA 3′ UTR target clone (Genecopoeia, Rockville, MD) was used. The expression clones were based on the peZX-MT51 vector containing dual reporter genes, encoding *Gaussia* luciferase (GLuc) and secreted alkaline phosphatase (SEAP). SEAP serves as an internal control for normalization of transfection efficiency and cell viability. A miTarget miRNA 3′ UTR target clone containing the CORIN 3′ UTR (accession number NM_001278585.1) was cotransfected with 40 nM precursor miR-1 (Life Technologies), scrambled pre-miRNA, anti-miR-1 LNA antisense inhibitor, or scrambled anti-miR inhibitor into iPS-CM. Sixteen nucleotides, including the predicted miR-1 target site of the CORIN 3′ UTR, were deleted using the Phusion site-directed mutagenesis kit (Thermo Fisher) according to the manufacturer’s instructions, using forward primer 5′-AAT AGA TAC TAC CTG CAA TTT TAT ACA TGT-3′ and reverse primer 5′-CTG AGG CCG TCC AGG GGG-3′. Deletion of the miR-1 target sequence was confirmed with Sanger sequencing. An empty miTarget vector was transfected as a control. SEAP and GLuc activities were measured 72 h after transfection using the Secrete-Pair dual-luminescence assay kit (Genecopoeia) on a Glomax 20/20 luminometer (Promega, Madison, WI). Results were expressed as the ratio of GLuc and SEAP.

**Statistical analysis.** Data are presented as mean values and standard errors of the means (SEM). Statistical significance of differences between data for different experimental groups was assessed with t tests. Adjustment of P values for multiple comparisons was performed according to the principle of false discovery rate (53). Thresholds for statistical significance were *P* < 0.05 or *q* < 0.05. All statistical analyses and analyses of enzyme kinetics were performed in Prism version 7.00 (GraphPad, La Jolla, CA).

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at https://doi.org/10.1128/MCB.00271-19.

**SUPPLEMENTAL FILE 1**

PDF file, 0.1 MB.

**ACKNOWLEDGMENTS**

This work was supported by grants from the Swedish Heart and Lung Foundation (grants number 2016-0134 and 2016-0315), the Swedish Research Council (grant number 2017-02554), the European Research Council (grant number ERC-STG-2015-679242), the Crafoord Foundation, the Elsa Golje Foundation, the Royal Physiographic Society, Lars Hiertas Minne, the Märta Winkler Foundation, governmental funding of clinical research within the Swedish National Health Service, a generous donation from the Knut and Alice Wallenberg foundation to the Wallenberg Center for Molecular Medicine in Lund, the Swedish Research Council (Linnaeus grant Dnr 349-2006-237 and Strategic Research Area Exodiab grant Dnr 2009-1039), and a grant from the Swedish Foundation for Strategic Research (grant Dnr IRC15-0067) to the Lund University Diabetes Center.

**REFERENCES**

1. Flynn TG, de Bold ML, de Bold AJ. 1983. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun 117:859–865. https://doi.org/10.1016/0006-291X(83)91675-3.

2. Napier MA, Vandlen RL, Albers-Schönberg G, Nutt RF, Brady S, Lyle T, Winquist R, Faison EP, Heinle LA, Blaine EH. 1984. Specific membrane adenyl cyclase activators increase cyclic AMP in atrial myocytes. J Biol Chem 259:1568–1575. https://doi.org/10.1016/S0021-9258(17)36950-X.

3. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. 2014. Angiotensin-nephrilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004. https://doi.org/10.1056/NEJMoa1409027.

4. Wu F, Yan W, Pan J, Morser J, Wu Q. 2002. Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J Biol Chem 277:16900–16905. https://doi.org/10.1074/jbc.M201503200.

5. Chan JCY, Knudson O, Wu F, Morser J, Dole WP, Wu Q. 2005. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci USA 102:785–790. https://doi.org/10.1073/pnas.0407234102.

6. Wang W, Shen J, Cui Y, Jiang J, Chen S, Peng J, Wu Q. 2012. Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice. Kidney Int 82:26–33. https://doi.org/10.1038/ki.2012.41.

7. Dries DL, Victor RG, Rame JE, Cooper RS, Wu X, Zhu X, Leonard D, Ho SI, Wu Q, Post W, Drazner MH. 2005. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 112:2403–2410. https://doi.org/10.1161/CIRCULATIONAHA.105.568881.

8. Rame JE, Drazner MH, Post W, Peshock R, Lima J, Cooper RS, Dries DL.
11. Langenickel TH, Pagel I, Buttgeriet J, Tenner K, Lindner M, Dietz R, Arora P, Wu C, Khan AM, Bloch DB, Davis-Dusenbery BN, Ghorbani A, Wang W, Liao X, Fukuda K, Knappe S, Wu F, Dries DL, Qin J, Wu Q. 2008. MicroRNA-1 overexpression blunts cardiomyocyte hypertrophy elicited by thyroid hormone. J Cell Physiol 223:3360–3368. https://doi.org/10.1002/jcp.25781.

28. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, Chen G, Wang Z. 2007. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486–491. https://doi.org/10.1038/nm1569.

20. Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. Mol Cell 36:9–15. https://doi.org/10.1016/j.molcel.2009.03.008.

13. Chen S, Sen S, Young D, Wang W, Moravec CS, Wu Q. 2010. Protease elements in their promoters. J Biol Chem 277:38390–38398. https://doi.org/10.1074/jbc.M205666200.

5. Li CY, Lee HC, Fu CY, Ding YY, Chen JS, Lee MH, Huang WJ, Tsai HJ. 2013. Classification of various muscular tissues using miRNA profiling. J Mol Cell Cardiol 56:112–119. https://doi.org/10.1016/j.yjmcc.2013.04.009.

34. Wang L, Yuan Y, Li J, Ren H, Cai Q, Chen X, Liang H, Shan H, Fu ZD, Gao X, Lu Y, Yang B, Zhang Y. 2015. MicroRNA-1 aggravates cardiac oxidative stress by post-transcriptional modification of the antioxidant network. Cell Stress Chaperones 20:411–420. https://doi.org/10.1007/s12192-014-0559-9.

61. Dong H, Li X, Zhang S, Wang Y, Guo Z, Li C, Wang T, Duan Y. 2015. miR-1 overexpression blunts cardiomyocyte hypertrophy. J Biol Chem 290:1316–1324. https://doi.org/10.1074/jbc.M114.586144.

36. Zhao Y, Shen X, Tang T, Wu CL. 2017. Weak regulation of many targets is cumulatively powerful—an evolutionary perspective on microRNA functionality. Mol Biol Evol 34:3041–3046. https://doi.org/10.1093/molbev/msx260.

17. Akhtar I, Brennecke J, Russell RB, Cohen SM. 2003. Identification of Drosophila microRNA targets. PLoS Biol 1:e60. https://doi.org/10.1371/journal.pbio.0000060.

27. Zhao Y, Shen X, Tang T, Wu CL. 2017. Weak regulation of many targets is cumulatively powerful—an evolutionary perspective on microRNA functionality. Mol Biol Evol 34:3041–3046. https://doi.org/10.1093/molbev/msx260.

17. Akhtar I, Brennecke J, Russell RB, Cohen SM. 2003. Identification of Drosophila microRNA targets. PLoS Biol 1:e60. https://doi.org/10.1371/journal.pbio.0000060.

27. Zhao Y, Shen X, Tang T, Wu CL. 2017. Weak regulation of many targets is cumulatively powerful—an evolutionary perspective on microRNA functionality. Mol Biol Evol 34:3041–3046. https://doi.org/10.1093/molbev/msx260.

29. Sowers JR, Schmitz AE, Kass DA. 2007. The pathophysiology of hypertrophic cardiomyopathy. J Am Coll Cardiol 49:1075–1083. https://doi.org/10.1016/j.jacc.2006.07.016.

16. Aggarwal V, Bell GW, Nam J-W, Bartel DP. 2015. Predicting effective microRNA target sites in mammalian mRNAs. Elife 4:1–38. https://doi.org/10.7554/elif.05005.

21. Bashir A, Shahbaz W, Lakhanpal A, Jawaid N, Ali S, Khan S, Nadeem M, Arif M, Ahmad R, Abid M, Aslam S, et al. 2018. miR-1 and miR-133a target APOB in opposing roles during angiogenesis in zebrafish embryos. Nat Commun 9:4282. https://doi.org/10.1038/s41467-018-05329-7.

32. Gao Y, Wang Z. 2007. The muscle-specific microRNA miR-1 regulates cardiac hypertrophy and arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486–491. https://doi.org/10.1038/nm1569.

18. Lu LF, Liston A. 2009. MicroRNA in the immune system, microRNA as an immune checkpoint. Immunology 127:291–298. https://doi.org/10.1111/j.1365-2567.2009.06.016.

19. Lu LF, Liston A. 2009. MicroRNA in the immune system, microRNA as an immune checkpoint. Immunology 127:291–298. https://doi.org/10.1111/j.1365-2567.2009.06.016.

25. Lall S, Grün D, Krek A, Chen K, Wang YL, Dewey CN, Sood P, Colombo T, Stark A, Brennecke J, Russell RB, Cohen SM. 2003. Identification of microRNA target sites in mammalian mRNAs. Elife 4:1–38. https://doi.org/10.7554/elif.05005.

27. Zhao Y, Shen X, Tang T, Wu CL. 2017. Weak regulation of many targets is cumulatively powerful—an evolutionary perspective on microRNA functionality. Mol Biol Evol 34:3041–3046. https://doi.org/10.1093/molbev/msx260.

29. Sowers JR, Schmitz AE, Kass DA. 2007. The pathophysiology of hypertrophic cardiomyopathy. J Am Coll Cardiol 49:1075–1083. https://doi.org/10.1016/j.jacc.2006.07.016.

16. Aggarwal V, Bell GW, Nam J-W, Bartel DP. 2015. Predicting effective microRNA target sites in mammalian mRNAs. Elife 4:1–38. https://doi.org/10.7554/elif.05005.

21. Bashir A, Shahbaz W, Lakhanpal A, Jawaid N, Ali S, Khan S, Nadeem M, Arif M, Ahmad R, Abid M, Aslam S, et al. 2018. miR-1 and miR-133a target APOB in opposing roles during angiogenesis in zebrafish embryos. Nat Commun 9:4282. https://doi.org/10.1038/s41467-018-05329-7.

32. Gao Y, Wang Z. 2007. The muscle-specific microRNA miR-1 regulates cardiac hypertrophy and arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486–491. https://doi.org/10.1038/nm1569.

18. Lu LF, Liston A. 2009. MicroRNA in the immune system, microRNA as an immune checkpoint. Immunology 127:291–298. https://doi.org/10.1111/j.1365-2567.2009.06.016.

19. Lu LF, Liston A. 2009. MicroRNA in the immune system, microRNA as an immune checkpoint. Immunology 127:291–298. https://doi.org/10.1111/j.1365-2567.2009.06.016.

25. Lall S, Grün D, Krek A, Chen K, Wang YL, Dewey CN, Sood P, Colombo T, Stark A, Brennecke J, Russell RB, Cohen SM. 2003. Identification of microRNA target sites in mammalian mRNAs. Elife 4:1–38. https://doi.org/10.7554/elif.05005.
44. Ogawa E, Saito Y, Kuwahara K, Harada M, Miyamoto Y, Hamanaka I, Kajiyama N, Takahashi N, Izumi T, Kishimoto I, Naruse Y, Mori N, Nakao K. 2002. Fibronectin signaling stimulates BNP gene transcription by inhibiting neuron-restrictive silencer element-dependent repression. Cardiovasc Res 53:451–459. https://doi.org/10.1016/s0008-6363(01)00492-8.

45. Piccini I, Rao J, Seebohm G, Greber B. 2015. Human pluripotent stem cell-derived cardiomyocytes: genome-wide expression profiling of long-term in vitro maturation in comparison to human heart tissue. Genomics Data 4:69. https://doi.org/10.1016/j.gdata.2015.03.008.

46. Barbuti A, Robinson RB. 2015. Stem cell-derived nodal-like cardiomyocytes as a novel pharmacologic tool: insights from sinoatrial node development and function. Pharmacol Rev 67:368. https://doi.org/10.1124/pr.114.009597.

47. Karakikes I, Chaanine AH, Kang S, Mukete BN, Jeong D, Zhang S, Hajjar RJ, Lebeche D. 2013. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2:e000078. https://doi.org/10.1161/JAHA.113.000078.

48. Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, Lee K-H, Ma Q, Kang PM, Goulub TR, Pu WT. 2009. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 29:2193–2204. https://doi.org/10.1128/MCB.01222-08.

49. Belevych AE, Sansom SE, Terentyeva R, Ho HT, Nishijima Y, Martin MM, Jindal HK, Roehrich JA, Kunitomo Y, Abdellatif M, Carnes CA, Elton TS, Gyorke S, Terentyev D. 2011. MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One 6:e28324. https://doi.org/10.1371/journal.pone.0028324.

50. Rupaimoole R, Slack FJ. 2017. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16:203–222. https://doi.org/10.1038/nrd.2016.246.

51. Heidersbach A, Saxby C, Carver-Moore K, Huang Y, Ang YS, de Jong PJ, Ivey KN, Srivastava D. 2013. MicroRNA-1 regulates sarcomere formation and suppresses smooth muscle gene expression in the mammalian heart. Elife 2:e01323. https://doi.org/10.7554/eLife.01323.

52. Minami T, Kuwahara K, Nakagawa Y, Takaoka M, Kinoshita H, Nekao K, Kuwabara Y, Yamada Y, Yamada C, Shibata J, Usami S, Yasuno S, Nishi-kimi T, Ueshima K, Sato M, Nakano H, Seno T, Kawahito Y, Sobue K, Kimura A, Nagai R, Nakao K. 2012. Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice. EMBO J 31:4428–4440. https://doi.org/10.1038/emboj.2012.296.

53. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57:289–300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x.

54. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249–264. https://doi.org/10.1093/biostatistics/4.2.249.